Fresenius Medical Care AG (NYSE:FMS) Sees Large Increase in Short Interest

Fresenius Medical Care AG (NYSE:FMS) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling 730,200 shares, a growth of 6.9% from the September 30th total of 683,300 shares. Based on an average daily volume of 294,500 shares, the short-interest ratio is presently 2.5 days.

Institutional Investors Weigh In On Fresenius Medical Care

Several institutional investors have recently added to or reduced their stakes in FMS. Allworth Financial LP increased its stake in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after purchasing an additional 581 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares during the last quarter. ORG Partners LLC acquired a new position in shares of Fresenius Medical Care during the 1st quarter worth about $110,000. ORG Wealth Partners LLC acquired a new position in shares of Fresenius Medical Care during the 3rd quarter worth about $112,000. Finally, SageView Advisory Group LLC acquired a new position in shares of Fresenius Medical Care during the 1st quarter worth about $127,000. 8.25% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on FMS. StockNews.com began coverage on shares of Fresenius Medical Care in a research report on Friday. They issued a “strong-buy” rating for the company. Truist Financial upped their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $23.00.

Fresenius Medical Care Trading Up 0.9 %

FMS stock traded up $0.17 during midday trading on Friday, reaching $19.71. The company’s stock had a trading volume of 234,741 shares, compared to its average volume of 369,943. Fresenius Medical Care has a 52 week low of $16.66 and a 52 week high of $22.76. The stock has a market cap of $11.57 billion, a PE ratio of 20.14, a price-to-earnings-growth ratio of 0.93 and a beta of 0.91. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The business’s 50-day simple moving average is $20.32 and its 200-day simple moving average is $20.17.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.38. The company had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. As a group, sell-side analysts expect that Fresenius Medical Care will post 1.52 EPS for the current year.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.